Literature DB >> 10052896

Susceptibility of multidrug-resistant strains of Mycobacterium tuberculosis to amoxycillin in combination with clavulanic acid and ethambutol.

G Abate1, H Miörner.   

Abstract

Thirty clinical isolates of Mycobacterium tuberculosis, 20 of which were multidrug-resistant (MDR), were tested for susceptibility to different combinations of amoxycillin, clavulanic acid and subinhibitory concentrations of ethambutol. beta-Lactamase production was assessed semiquantitatively with the nitrocefin method and susceptibility testing was performed with the BACTEC method. All isolates were beta-lactamase positive and were resistant to 16 mg/L amoxycillin. The MIC of amoxycillin in combination with clavulanic acid was > or =2 mg/L for 27/30 (90%) isolates. Addition of subinhibitory concentrations of ethambutol significantly reduced the MIC of amoxycillin for all tested isolates. Twenty-nine (97%) isolates had an MIC of amoxycillin of < or =0.5 mg/L when subinhibitory concentrations of ethambutol were added; this is well below the concentrations achievable in serum and tissue.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10052896     DOI: 10.1093/jac/42.6.735

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics.

Authors:  Feng Wang; Craig Cassidy; James C Sacchettini
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

2.  In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with β-lactamase inhibitors.

Authors:  Yasuhiro Horita; Shinji Maeda; Yuko Kazumi; Norio Doi
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

3.  Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Authors:  L Davies Forsman; C G Giske; J Bruchfeld; T Schön; P Juréen; K Ängeby
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

4.  Morphological features and signature gene response elicited by inactivation of FtsI in Mycobacterium tuberculosis.

Authors:  Richard A Slayden; John T Belisle
Journal:  J Antimicrob Chemother       Date:  2008-12-24       Impact factor: 5.790

Review 5.  Multidrug-resistant tuberculosis in Ethiopia: efforts to expand diagnostic services, treatment and care.

Authors:  Fantahun Biadglegne; Ulrich Sack; Arne C Rodloff
Journal:  Antimicrob Resist Infect Control       Date:  2014-10-03       Impact factor: 4.887

6.  Prevalence and drug resistance profile of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients attending two public hospitals in East Gojjam zone, northwest Ethiopia.

Authors:  Kelemework Adane; Gobena Ameni; Shiferaw Bekele; Markos Abebe; Abraham Aseffa
Journal:  BMC Public Health       Date:  2015-06-20       Impact factor: 3.295

7.  The Antituberculosis Drug Ethambutol Selectively Blocks Apical Growth in CMN Group Bacteria.

Authors:  Karin Schubert; Boris Sieger; Fabian Meyer; Giacomo Giacomelli; Kati Böhm; Angela Rieblinger; Laura Lindenthal; Nadja Sachs; Gerhard Wanner; Marc Bramkamp
Journal:  mBio       Date:  2017-02-07       Impact factor: 7.867

8.  Anti tuberculosis drug resistance in west of iran.

Authors:  Parviz Mohajeri; Baharak Norozi; Sara Atashi; Abbas Farahani
Journal:  J Glob Infect Dis       Date:  2014-07

9.  Drug resistance of Mycobacterium tuberculosis isolates from tuberculosis lymphadenitis patients in Ethiopia.

Authors:  Fantahun Biadglegne; Belay Tessema; Ulrich Sack; Arne C Rodloff
Journal:  Indian J Med Res       Date:  2014-07       Impact factor: 2.375

Review 10.  Developing New Antimicrobial Therapies: Are Synergistic Combinations of Plant Extracts/Compounds with Conventional Antibiotics the Solution?

Authors:  Matthew J Cheesman; Aishwarya Ilanko; Baxter Blonk; Ian E Cock
Journal:  Pharmacogn Rev       Date:  2017 Jul-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.